via The Scientist RSS https://ift.tt/VkSHbi1 The ACTIV-6 trial reports that people who took the drug for three days may have spent slightly less time feeling unwell with SARS-CoV-2, but fails to find differences in disease progression between the treatment and placebo groups. https://ift.tt/uHB9V5i June 13, 2022 at 11:58PM